Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction

Renal Failure Clinical Trial

Official title:

A Phase 1 and Pharmacokinetic Study of Dabrafenib (GSK2118436B) in Patients With BRAFV600X Mutations and Renal or Hepatic Dysfunction

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01907802
• Other study ID #: NCI-2013-01338
• Secondary ID: NCI-2013-01338MC
• Status: Terminated
• Phase: Phase 1
• Start date: August 23, 2013
• Est. completion date: December 16, 2015

Study information

• Verified date: August 2018
• Source: National Cancer Institute (NCI)
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase I trial studies the side effects and best dose of dabrafenib in treating patients with solid tumors and kidney or liver dysfunction. Dabrafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Description:

PRIMARY OBJECTIVES:

I. To determine the toxicity profile and the maximum tolerated doses (MTDs) of dabrafenib in patients with v-raf murine sarcoma viral oncogene homolog B1 (BRAF)^V600X mutations and renal or hepatic dysfunction.

SECONDARY OBJECTIVES:

I. To assess for tumor response and various times to clinical event. II. To provide dosing recommendations for dabrafenib in patients with varying degrees of hepatic and renal dysfunction for possible inclusion in the label.

TERTIARY OBJECTIVES:

I. To assess the pharmacokinetic and pharmacogenetic profile of dabrafenib and active metabolites.

OUTLINE: This is a dose-escalation study.

Patients receive dabrafenib orally (PO) twice daily (BID) on days 1-28 (once daily [QD] on day 1 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 days.

Other known NCT identifiers

• NCT02925689

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 8
• Est. completion date: December 16, 2015
• Est. primary completion date: December 16, 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• PRE-REGISTRATION ELIGIBILITY CRITERIA

• Willing to provide tissue as required per protocol for central BRAF^V600X mutation testing

• NOTE: patients with prior BRAF^600X testing that demonstrate a mutation at V600X will be allowed to enroll prior to central testing if the assay was performed at a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory assay; this includes THxID, BRAF Detection Kit, Cobas 4800 BRAF600 mutation test and other CLIA-certified assays available at participating institutions

• Patients with unknown BRAF^600X status: histologically confirmed melanoma, papillary thyroid, cholangiocarcinoma or testicular cancer that is metastatic or unresectable and for which the investigator feels a BRAF^600X targeted agent is a reasonable treatment

• NOTE: patient must be screened by central BRAF testing and must demonstrate a V600 mutation prior to start of study agent

• Note: other tumor types without known BRAF^600X mutations will not be eligible for central testing

• Ability to understand and willingness to sign written informed consent

• Life expectancy of > 3 months

• REGISTRATION ELIGIBILITY CRITERIA

• Patients with known BRAF^V600X mutation: patients must have BRAF^V600X mutated, histologically confirmed cancer that is metastatic or unresectable and for which curative or standard therapies do not exist or are no longer effective

• NOTE: colorectal cancers with BRAF mutations ARE NOT allowed

• NOTE: any mutation at the V600 position that results in a change from V (valine) is allowed; this includes E, D, K, R or other mutations not noted here at the V600 position

• Any number of the following prior therapies is allowed:

• Chemotherapy >= 28 days prior to registration

• Mitomycin C/nitrosoureas >= 42 days prior to registration

• Immunotherapy >= 28 days prior to registration

• Biologic therapy >= 28 days prior to registration

• Radiation therapy >= 28 days prior to registration

• Radiation to < 25% of bone marrow

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (Karnofsky >= 70%)

• Able to swallow and retain oral medication and must not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels

• Absolute neutrophil count (ANC) >= 1.2 x 10^9/L

• Hemoglobin >= 9 g/dL

• Platelets >= 100 x 10^9/L

• Albumin >= 2.5 g/dL

• NOTE: this applies to patient in the normal and renal dysfunction cohorts (N, R3 and R4); abnormal albumin is allowed for patients in the liver dysfunction cohorts

• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional upper limit of normal (ULN)

• NOTE: this applies to patient in the normal and renal dysfunction cohorts (N, R3 and R4); patients with elevated AST and/or ALT may be assigned to liver dysfunction cohorts

• Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) =< 1.3 x institutional ULN; subjects receiving anticoagulation treatment may be allowed to participate with INR established within the therapeutic range prior to randomization

• NOTE: this applies to patient in the normal and renal dysfunction cohorts (N, R3 and R4); elevated PT/INR is allowed for patients in the liver dysfunction cohorts

• Left ventricular ejection fraction >= institutional lower limit of normal (LLN) by echocardiogram (ECHO)

• Hepatic and renal function meeting the strata below:

• Group N: Hepatic: normal function (bilirubin =< ULN; AST =< ULN); renal: normal function (creatinine clearance [CrCl] >= 60 mL/min as estimated by the Cockcroft and Gault equation)

• Group R3: Hepatic: normal function (bilirubin =< ULN; AST =< ULN); renal: severe dysfunction (CrCl >= 15 and < 30 mL/min as estimated by the Cockcroft and Gault equation)

• Group R4: Hepatic: normal function (bilirubin =< ULN; AST =< ULN; renal: renal failure (hemodialysis)

• Group H1: Hepatic: mild dysfunction (bilirubin =< ULN; AST > ULN); renal:

acceptable function (CrCl >= 60 mL/min as estimated by the Cockcroft and Gault equation)

• Group H2: Hepatic: moderate dysfunction (bilirubin > ULN and =< 3 x ULN; AST > ULN); renal: acceptable function (CrCl>== 60 mL/min as estimated by the Cockcroft and Gault equation)

• Group H3: Hepatic: severe dysfunction (bilirubin > 3 x ULN and up to investigators discretion; AST > ULN); renal: acceptable function (CrCl >= 60 mL/min as estimated by the Cockcroft and Gault equation)

• Women of childbearing potential must have a negative serum pregnancy test =< 7 days prior to registration

• Women of child-bearing potential and men must agree to use adequate contraception (barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 1 month after completion of dabrafenib administration

• Ability to understand and the willingness to sign a written informed consent document

• Willingness to provide blood and tissue samples as required per protocol

• Patients with a history of clinical benefit from prior RAF inhibitor therapy, as judged by the investigator, will be allowed

Exclusion Criteria:

• Patients with active biliary obstruction; NOTE: patients for which a shunt has been in place for at least 10 days prior to the first dose of dabrafenib are allowed

• Reduced left ventricular ejection fraction (< 50%) or other evidence of cardiac dysfunction as determined by the investigator

• Use of an investigational anti-cancer drug within 28 days preceding the first dose of dabrafenib

• Patients receiving any medications or substances that are strong inhibitors or inducers of cytochrome P450, family 3, subfamily A (CYP3A) or cytochrome P450 family 2, subfamily C, polypeptide 8 (CYP2C8) are ineligible

• For patients on intermediate inducers or inhibitors, attempts should be made to switch to an alternative agent or delay enrollment until treatment course with concomitant agent completed; if not possible, patient may be enrolled if it is felt to be in the patients best interest as decided by the investigator

• Weak inhibitors of CYP3A or CYP2C8 should be used with caution and attempts made to limit their use or find alternative agents, if possible

• Warfarin use is provisionally allowed

• Unresolved toxicity of National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0 (NCI CTCAE v4.0) grade 2 or higher from previous anti-cancer therapy, except alopecia

• Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; Note: patients not on antiretroviral therapies are eligible for this study

• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, diabetes mellitus, hypertension, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

• Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection

• Presence of malignancy other than the study indication under this trial within 5 years of study enrollment

• History or evidence of cardiovascular risks including any of the following:

• QT interval corrected for heart rate using the Bazett's formula QTcB >= 480 msec

• History of acute coronary syndromes (including myocardial infarction or unstable angina), coronary angioplasty, or stenting within the past 24 weeks prior to randomization

• History or evidence of current class II, III, or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system

• Intra-cardiac defibrillators

• Abnormal cardiac valve morphology (>= grade 2) documented by ECHO; (subjects with grade 1 abnormalities [i.e., mild regurgitation/stenosis] can be entered on study); subjects with moderate valvular thickening should not be entered on study

• History or evidence of current clinically significant uncontrolled cardiac arrhythmias; clarification: subjects with atrial fibrillation controlled for > 30 days prior to dosing are eligible

• Treatment refractory hypertension defined as a blood pressure of systolic > 140 mmHg and/or diastolic > 90 mm Hg which cannot be controlled by anti- hypertensive therapy

• Brain metastases that are symptomatic or untreated or not stable for >= 3 months (must be documented by imaging) or requiring corticosteroids; subjects on a stable dose of corticosteroids > 1 month or who have been off corticosteroids for at least 2 weeks can be enrolled with approval of the Cancer Therapy Evaluation Program (CTEP) medical monitor; subjects must also be off enzyme-inducing anticonvulsants for > 4 weeks

• History of acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting within the past 24 weeks; class II, III, or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system; or history of known cardiac arrhythmias unless it has been stably controlled

• History of allergic reactions attributed to compounds of similar chemical or biologic composition to dabrafenib or other agents used in this study

• Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with dabrafenib

• Any condition or medical problem in addition to the underlying malignancy and organ dysfunction which the investigator feels would pose unacceptable risk

Related Conditions & MeSH terms

• BRAF Gene Mutation
• Hepatic Complication
• Renal Failure
• Renal Insufficiency
• Solid Neoplasm

Intervention

Drug:
• Dabrafenib
Given PO

Other:
• Laboratory Biomarker Analysis
Correlative studies
• Pharmacogenomic Study
Correlative studies
• Pharmacological Study
Correlative studies

Locations

Country	Name	City	State
Canada	University Health Network-Princess Margaret Hospital	Toronto	Ontario
United States	University of Colorado Hospital	Aurora	Colorado
United States	Johns Hopkins University/Sidney Kimmel Cancer Center	Baltimore	Maryland
United States	Dana-Farber Cancer Institute	Boston	Massachusetts
United States	University of Chicago Comprehensive Cancer Center	Chicago	Illinois
United States	Case Western Reserve University	Cleveland	Ohio
United States	Ohio State University Comprehensive Cancer Center	Columbus	Ohio
United States	Wayne State University/Karmanos Cancer Institute	Detroit	Michigan
United States	City of Hope Comprehensive Cancer Center	Duarte	California
United States	Mayo Clinic in Florida	Jacksonville	Florida
United States	USC / Norris Comprehensive Cancer Center	Los Angeles	California
United States	University of Wisconsin Hospital and Clinics	Madison	Wisconsin
United States	Rutgers Cancer Institute of New Jersey	New Brunswick	New Jersey
United States	University of Pittsburgh Cancer Institute (UPCI)	Pittsburgh	Pennsylvania
United States	Mayo Clinic	Rochester	Minnesota
United States	University of California Davis Comprehensive Cancer Center	Sacramento	California
United States	Washington University School of Medicine	Saint Louis	Missouri
United States	City of Hope South Pasadena	South Pasadena	California

Sponsors (2)

Lead Sponsor	Collaborator
National Cancer Institute (NCI)	Glaxosmithkline Biologicals S.A.

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Pharmacokinetic profile of dabrafenib	Descriptive statistics and statistical plots will form the basis of presentation of biomarker, pharmacokinetic and pharmacogenetic studies. Clinical response and toxicity profile for patients will be correlated with the pharmacokinetic (PK) parameters and key polymorphisms in gene.	Days 1 and 15 of course 1, and day 1 of all subsequent courses
Other	Pharmacogenetic profile of dabrafenib	Descriptive statistics and statistical plots will form the basis of presentation of biomarker, pharmacokinetic and pharmacogenetic studies. Clinical response and toxicity profile for patients will be correlated with the PK parameters and key polymorphisms in gene.	Day 1 prior to treatment
Primary	Incidence of toxicities graded according to NCI CTCAE v4.0	Overall toxicity incidence as well as toxicity profiles by dose level and patient will be explored and summarized. Frequency distributions, graphical techniques and other descriptive measures will form the basis of these analyses.	Up to 30 days after completion of study treatment
Primary	MTD of dabrafenib, defined as the highest dose level that is estimated to induce a dose-limiting toxicity rate less than 33.3% by the two-way isotonic regression, graded according to NCI CTCAE v4.0	Overall toxicity incidence as well as toxicity profiles by dose level and patient will be explored and summarized. Frequency distributions, graphical techniques and other descriptive measures will form the basis of these analyses.	Up to 28 days
Secondary	Incidence of adverse events graded according to NCI CTCAE v4.0	The number and severity of all adverse events (overall, by dose level, and by tumor group) will be tabulated and summarized for the three patient groups. The grade 3+ adverse events will also be described and summarized in a similar fashion.	Up to 30 days after completion of study treatment
Secondary	Best response, defined as the best objective status recorded from the start of treatment until disease progression/recurrence, measured by modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria	Responses will be summarized by simple descriptive summary statistics delineating complete and partial responses as well as stable and progressive disease.	Up to 30 days after completion of study treatment
Secondary	Time until any treatment-related toxicity	The data on time-related variables will be summarized descriptively.	Up to 30 days after completion of study treatment
Secondary	Time until treatment related grade 3+ toxicity	The data on time-related variables will be summarized descriptively.	Up to 30 days after completion of study treatment
Secondary	Time until hematologic nadirs (white blood cells, ANC, platelets)	The data on time-related variables will be summarized descriptively.	Up to 30 days after completion of study treatment
Secondary	Time to progression	The data on time-related variables will be summarized descriptively.	Up to 30 days after completion of study treatment
Secondary	Time to treatment failure	The data on time-related variables will be summarized descriptively.	Time from registration to documentation of progression, unacceptable toxicity, or refusal to continue participation by the patient, assessed up to 30 days after completion of study treatment